Paul Tudor Jones Biocryst Pharmaceuticals Inc Transaction History
Tudor Investment Corp Et Al
- $19.2 Billion
- Q2 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 103,002 shares of BCRX stock, worth $839,466. This represents 0.0% of its overall portfolio holdings.
Number of Shares
103,002Holding current value
$839,466% of portfolio
0.0%Shares
17 transactions
Others Institutions Holding BCRX
# of Institutions
260Shares Held
174MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$163 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$153 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$102 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$76.2 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$71.9 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.52B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...